$1.530
-0.020 (-1.29%)At close
- High
- 1.587
- Open
- 1.540
- VWAP
- 1.54
- Volume
- 24.82K
- Mkt Cap
- —
- Low
- 1.500
- Amount
- 38.20K
- EV/EBITDA, TTM
- 0.00
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities.
AI analysis of SL Science Holding Ltd (SLBT)
SellSL Science Holding Ltd (SLBT) is not a good buy right now due to significant financial instability and poor performance metrics. The current price is $1.51, and the company has reported a staggering year-to-date change of -73.97%. Additionally, the current ratio has dropped to 0.00, indicating severe liquidity issues, and the forward P/E ratio is 0, suggesting no earnings expectations. The main risk is the high debt-to-equity ratio of 882.89%, which poses a serious threat to financial stability.
Valuation Metrics
News
9.009-27NASDAQ.COMSL Science Holding Reports Positive Data for Glioblastoma Treatment
9.008-27NASDAQ.COMSL Science Holding Files New Drug Master File with FDA
9.008-27NewsfilterSL Science Files New Drug Master File with FDA
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
- 8.507-17Newsfilter
SL Science Showcases γδ T Cell Therapy for Glioblastoma
SLBT FAQ — answered by Alphio AI
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities. It operates in the Healthcare sector.
SL Science Holding Ltd (SLBT) is not a good buy right now due to significant financial instability and poor performance metrics. The current price is $1.51, and the company has reported a staggering year-to-date change of -73.97%. Additionally, the current ratio has dropped to 0.00, indicating severe liquidity issues, and the forward P/E ratio is 0, suggesting no earnings expectations. The main risk is the high debt-to-equity ratio of 882.89%, which poses a serious threat to financial stability.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.